Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Holdings Lessened by Algert Global LLC

Algert Global LLC decreased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 27.3% in the third quarter, Holdings Channel.com reports. The firm owned 54,983 shares of the biopharmaceutical company’s stock after selling 20,631 shares during the period. Algert Global LLC’s holdings in Celldex Therapeutics were worth $1,869,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in CLDX. KBC Group NV lifted its stake in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics during the 2nd quarter valued at approximately $76,000. CANADA LIFE ASSURANCE Co grew its stake in shares of Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 955 shares during the last quarter. Quest Partners LLC increased its position in Celldex Therapeutics by 1,364.9% during the second quarter. Quest Partners LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $273,000 after acquiring an additional 6,879 shares during the period. Finally, Los Angeles Capital Management LLC boosted its holdings in Celldex Therapeutics by 9.5% in the 2nd quarter. Los Angeles Capital Management LLC now owns 7,371 shares of the biopharmaceutical company’s stock valued at $273,000 after purchasing an additional 638 shares during the period.

Insider Activity at Celldex Therapeutics

In related news, CEO Anthony S. Marucci acquired 11,500 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were purchased at an average price of $26.82 per share, with a total value of $308,430.00. Following the acquisition, the chief executive officer now directly owns 40,284 shares in the company, valued at $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Insiders own 3.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on CLDX. The Goldman Sachs Group started coverage on shares of Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research note on Monday, September 16th. Citigroup initiated coverage on Celldex Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $70.00 price objective for the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Finally, Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $62.25.

Celldex Therapeutics Stock Up 4.2 %

NASDAQ:CLDX opened at $27.89 on Thursday. Celldex Therapeutics, Inc. has a 12 month low of $22.93 and a 12 month high of $53.18. The company’s 50-day moving average price is $29.35 and its two-hundred day moving average price is $34.60. The firm has a market cap of $1.85 billion, a PE ratio of -10.85 and a beta of 1.60.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.